If you have been reading about triple agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-27. Numbers and descriptions here follow the published literature rather than marketing material.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
The sulcular epithelium is a thin, non-keratinized epithelial lining that forms the smooth inner wall of the gingival sulcus, extending from the gingival margin coronally to the dentogingival junction apically. The gingival sulcus normally measures 0.5–3 mm in healthy individuals; an increase beyond this range may indicate pseudopocket formation or periodontal disease. The sulcular epithelium primarily acts as the protective barrier against foreign substances while also playing a crucial immunological role due to its semi-permeable nature. Structural and functional changes in the sulcular epithelium are observed during the onset and progression of periodontal disease. In dental anatomy, the sulcular epithelium is that epithelium which lines the gingival sulcus. It is apically bounded by the junctional epithelium and meets the epithelium of the oral cavity at the height of the free gingival margin. The sulcular epithelium is nonkeratinized.
House Committee: oversees the amenities for members of the assembly such as housing, food, health-care and transport. Library Committee: is responsible for the maintenance and development of the state government and assembly library. Select Committee: is charged with the examination and development of specific legislation, preparing it for final passage. Committee on the Empowerment of Women: oversees schemes and programmes aimed to increase representation of women in society and economic sectors. Budget Committee: examines budget proposals for various organs and departments of the state government.
Buckwheat pancakes were a common food in American pioneer days. Buckwheat blinis form gluten-free Russian-style pancakes. Buckwheat is a permitted sustenance during fasting in several traditions. In India, on Hindu fasting days (Navaratri, Ekadashi, Janmashtami, Maha Shivaratri, etc.), fasting people in northern states of India eat foods made of buckwheat flour. Eating cereals such as wheat or rice is prohibited during such fasting days. While strict Hindus do not even drink water during their fast, others give up cereals and salt and instead eat non-cereal foods such as buckwheat (kuttu). In the Russian Orthodox tradition, it is eaten on the St. Philip fast. Buckwheat honey is dark, strong and aromatic. It is normally produced as a monofloral honey.
The shelf life of fats correlates with the degree of saturation: polyunsaturated fats are prone to autoxidation whereas saturated fats, being virtually inert in air, have very long shelf lives. Saturated fats tend to be more solid at room temperature. This property is important for margarine, one of the original uses for fat hydrogenation. However, an isomerization side reaction during fat hydrogenation can convert remaining unsaturated fats to the thermodynamically favored trans isomer.
Sources: en.wikipedia.org
== Further reading == Katz, Alan (1 May 2009), "Lab Automation Protocols and Virtual Workcells", Genetic Engineering & Biotechnology News, OMICS, vol. 29, no. 9, Mary Ann Liebert, pp. 40–41, ISSN 1935-472X, OCLC 77706455, archived from the original on 25 February 2012, retrieved 25 July 2009
The threading of the lasso tail is trapped either by disulfide bonds between ring and tail cysteine residues (class I lasso peptides), by steric effects due to bulky residues on the tail (class II lasso peptides), or both (class III lasso peptides). The compact structure makes lasso peptides frequently resistant to proteases or thermal unfolding.
In order to easily determine when the filter is spent, Kelly and his team developed a mask equipped with a sensor composed of carbon nanofibers assembled into repeating structures called photonic crystals that reflect specific wavelengths of light. The sensors exhibit an iridescent color that changes when the fibers absorb toxins.
== Toxicity == S2F10 was considered a potential chemical warfare pulmonary agent in World War II because it does not produce lacrimation or skin irritation, thus providing little warning of exposure. Disulfur decafluoride is a colorless gas or liquid with a sulfur dioxide (SO2)-like odor. Its toxicity is thought to be caused by its disproportionation in the lungs into SF6, which is inert, and SF4, which reacts with moisture to form sulfurous acid and hydrofluoric acid.
== History == In 1923 Louis Ruprecht, a graduate from Stevens Institute of Technology, founded Pulverizing Company with offices in New York City and a small machine shop in Elizabeth, New Jersey. The company focused its efforts in micronizing or size reduction of powder materials. The first machine patented was the Mikro-Pulverizer which accomplished powder size reduction by mechanically impacting material with the use of a hammer and screen. The business outgrew its facilities in Elizabeth and moved to Roswell Park in 1932. In ten more years the company had once more outgrown these facilities and moved to Summit, New Jersey where it currently resides. In May, 1942 the Summit location opened and was immediately contracted by the US Army and Navy to produce materials for World War II. From 1942 to 1945 the company produced parts for tanks, warships and airplanes. Over one million pounds of magnesium powder were produced for tracer bullets and flares. During this time the Summit location was heavily guarded. In 1954, Louis Ruprecht died and the company was sold to Metals Disintegration Company in Union, New Jersey. After a number of ownership changes, finally, in 1985 the company was sold to the Micron Powder Group and the name was changed to Hosokawa Micron Powder Systems. The company current operates in a 14,000 square foot facility in Summit, New Jersey.
Sources: en.wikipedia.org
Executions in Singapore are carried out by long drop hanging, and usually take place at dawn. Thirty-three offences—including murder, drug trafficking, terrorism, use of firearms and kidnapping—warrant the death penalty under Singaporean law. In 2012, Singapore amended its laws to exempt some offences from the mandatory death sentence. In a 2005 survey by The Straits Times, 95% of Singaporeans were of the view that their country should retain the death penalty. The support steadily fell throughout the years due to the increasing liberal opinions of society. Despite the decline, a large majority of the public remains supportive of the use of the death penalty, with more than 80% of Singaporeans believing that their country should retain the death penalty in 2021. The most recent executions conducted in Singapore took place on 9th September 2026, when a 44 year old Singaporean was hanged for trafficking in controlled drugs.
=== Bleeding time === Bleeding time was developed as a test of platelet function by Duke in 1910. Duke's test measured the time taken for bleeding to stop from a standardized wound in the ear lobe that was blotted every 30 seconds, considering less than 3 minutes as normal. Bleeding time has low sensitivity and specificity for mild to moderate platelet disorders and is no longer recommended for screening.
=== Further reading === Ball, S. J. The Cold War: An International History, 1947–1991 (1998). British perspective Beschloss, Michael, and Strobe Talbott. At the Highest Levels:The Inside Story of the End of the Cold War (1993) Braithwaite, Rodric et al. "Could the Soviet Union Have Survived? We ask four historians whether the demise of one of the 20th century's superpowers was as inevitable as it now seems." History Today (Oct 2020) 70#10 pp 8–10 [online]. Brooks, Stephen G., and William C. Wohlforth. "Power, globalization, and the end of the Cold War: Reevaluating a landmark case for ideas." International Security 25.3 (2001): 5-53. [online] Engel, Jeffrey A. When the World Seemed New: George H. W. Bush and the End of the Cold War (2017) Gaddis, John Lewis. The United States and the End of the Cold War: Implications, Reconsiderations, Provocations (1992) online Garthoff, Raymond. The Great Transition: American-Soviet Relations and the End of the Cold War (1994) online Goertz, Gary and Jack S. Levy, eds. Causal explanations, necessary conditions, and case studies: World War I and the End of the Cold War (2005), 10 essays from political scientists; online Hogan, Michael, ed. The End of the Cold War. Its Meaning and Implications (1992) articles from Diplomatic History Kalinovsky, Artemy M. "New Histories of the End of the Cold War and the Late Twentieth Century." Contemporary European History 27.1 (2018): 149–161. online Kegley Jr, Charles W. "How did the Cold War die? Principles for an autopsy." Mershon International Studies Review 38.Supplement_1 (1994): 11–41.
On July 9, Trump reversed a previously suspended military aid package to Ukraine following Russia's largest aerial assault on the country, involving hundreds of drones and missiles. The suspension, reportedly authorized by senior defense officials without Trump's prior knowledge. Trump expressed growing frustration with Russian president Vladimir Putin, accusing him of insincerity and relentless aggression, saying, "He wants to go all the way, just keep killing people, it's no good." The U.S. are discussing sending 10 Patriot missiles to Ukraine, and Trump said he is reviewing a proposed sanctions bill by Senator Lindsey Graham that would impose 500% tariffs on countries trading with Russia. Although Trump has previously mentioned secondary sanctions, none have been implemented so far, with the president citing their cost and waiting to see if a peace deal would emerge. On July 14, 2025, Trump threatened to impose 100% tariffs and secondary sanctions on countries purchasing Russian oil if Russia did not agree to a ceasefire within 50 days. Trump confirmed a summit meeting between him and Putin to be held on August 15, 2025, in Alaska The high-level summit at Joint Base Elmendorf–Richardson in Anchorage concluded without progress toward a ceasefire. Following the talks, Trump suggested the United States could assist Ukraine with surveillance flights or air defense support, while ruling out the deployment of ground troops.
=== Nonsurgical === Prevention of movement between the layers allows the tentative initial bond of fibrin to be reinforced by wound healing with a thin, strong, layer of scar. Avoiding certain positions for certain surgeries may have an effect. (In abdominoplasty, sitting upright with the knees bent and hips flexed will cause pressure across the lower abdomen and a tendency to seroma formation. The patient is best to stand or at least be semirecumbent). External pressure may help in immobilization, but also is thought to reduce the tendency of the fluid to leak out of vessels by increasing the backpressure on those fluid sources. Following breast augmentation or double mastectomy, binding the chest may be recommended for several weeks to minimize the risk of seromas.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.